Results 11 to 20 of about 3,126,313 (204)

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations [PDF]

Haematologica, 2014
Somatic insertions/deletions in the calreticulin gene have recently been discovered to be causative alterations in myeloproliferative neoplasms. A combination of qualitative and quantitative allele-specific polymerase chain reaction, fragment-sizing ...
Hajnalka Andrikovics, Tunde Krahling, Katalin Balassa, Gabriella Halm, Andras Bors, Magdalena Koszarska, Arpad Batai, Janos Dolgos, Judit Csomor, Miklos Egyed, Andrea Sipos, Peter Remenyi, Attila Tordai, Tamas Masszi   +13 more
doaj   +3 more sources

SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.

Future Oncology, 2022
Patients diagnosed with high-risk essential thrombocythemia (ET) have limited treatment options to reduce the risk of thrombosis and lessen the progression of the disease by targeting the molecular source.
S. Verstovsek, Norio Komatsu, H. Gill, J. Jin, Sung‐Eun Lee, H. Hou, Toshiaki Sato, A. Qin, Raymond W Urbanski, W. Shih, O. Zagrijtschuk, C. Zimmerman, R. Mesa   +12 more
semanticscholar   +1 more source

Increased cleavage of von Willebrand factor by ADAMTS13 may contribute strongly to acquired von Willebrand syndrome development in patients with essential thrombocythemia

Journal of Thrombosis and Haemostasis, 2022
Patients with essential thrombocythemia (ET) often experience bleeding associated with acquired von Willebrand syndrome (AVWS) when the platelet count is markedly increased.
Masayuki Kubo, K. Sakai, M. Hayakawa, H. Kashiwagi, H. Yagi, Y. Seki, Atsushi Hasegawa, Haruyuki Tanaka, I. Amano, Y. Tomiyama, M. Matsumoto   +10 more
semanticscholar   +1 more source

Essential Thrombocythemia among Patients with Myeloproliferative Neoplasms in Haematology Unit of a Tertiary Care Centre: A Descriptive Cross-sectional Study

Journal of Nepal Medical Association, 2022
Introduction: Essential thrombocythemia, a myeloproliferative condition with an increased number of circulating platelets, is a rare hematological malignancy. The aim of the study is to find out the prevalence of essential thrombocythemia among patients
Sanjit Kumar Sah, Sangam Shah, Sansar Babu Tiwari, Basanta Sharma Poudel, Biranmol Singh, Prakash Sharma, Sunil Sharma Acharya, Hritik Murarka, Sabin Thapaliya, Anjan Shrestha   +9 more
doaj   +1 more source

Mutations and thrombosis in essential thrombocythemia

Blood Cancer Journal, 2021
Dear Editor, Essential thrombocythemia (ET) constitutes one of the three JAK2/MPL/CALR-mutated myeloproliferative neoplasms (MPNs), which also include polycythemia vera (PV) and primary myelofibrosis (PMF).
P. Guglielmelli, N. Gangat, G. Coltro, T. Lasho, G. G. Loscocco, C. Finke, Erika Morsia, Benedetta Sordi, N. Szuber, C. Hanson, A. Pardanani, A. Vannucchi, A. Tefferi   +12 more
semanticscholar   +1 more source

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

Blood Cancer Journal, 2021
In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (MF, n = 56), and prefibrotic myelofibrosis (pre-PMF, n = 16), 15 major ...
T. Barbui, V. De Stefano, A. Álvarez-Larrán, A. Iurlo, A. Masciulli, A. Carobbio, A. Ghirardi, A. Ferrari, V. Cancelli, E. Elli, M. Andrade-Campos, Mercedes Gasior Kabat, J. Kiladjian, F. Palandri, G. Benevolo, V. García‐Gutiérrez, M. Fox, M. Foncillas, C. Morcillo, E. Rumi, S. Osorio, P. Papadopoulos, M. Bonifacio, Keina Susana Quiroz Cervantes, Miguel Sagues Serrano, G. Carreño-Tarragona, M. Sobas, F. Lunghi, A. Patriarca, B. Elorza, A. Angona, Elena Magro Mazo, S. Koschmieder, G. Carli, B. Cuevas, J. Hernández-Boluda, Emma Lopez Abadia, B. X. Cirici, P. Guglielmelli, M. Garrote, D. Cattaneo, R. Daffini, F. Cavalca, B. Bellosillo, L. Benajiba, N. Curto-Garcia, M. Bellini, S. Betti, C. Harrison, A. Rambaldi, A. Vannucchi   +50 more
semanticscholar   +1 more source

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia

Journal of Hematology & Oncology, 2021
In a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2 weeks after the second dose was significantly lower in the ten ...
F. Pimpinelli, F. Marchesi, G. Piaggio, D. Giannarelli, E. Papa, P. Falcucci, A. Spadea, M. Pontone, S. di Martino, V. Laquintana, Antonia Marina La Malfa, E. D. Di Domenico, O. di Bella, Gianluca Falzone, F. Ensoli, B. Vujovic, A. Morrone, G. Ciliberto, A. Mengarelli   +18 more
semanticscholar   +1 more source

Retinal neovascularization in the setting of -mutation positive essential thrombocythemia

SAGE Open Medical Case Reports, 2023
Patients with Calreticulin ( CALR ) mutation positive essential thrombocythemia are often thought of as having a “low-risk” of thrombotic complications.
Stanton P Heydinger, Marwan R Abdulaal, Angeline L Wang   +2 more
doaj   +1 more source

Young platelet millionaires with essential thrombocythemia

American journal of hematology/oncology, 2021
To the Editor: The platelet count threshold for World Health Organization classification system-compliant diagnosis of essential thrombocythemia (ET) is ≥450 × 10/L.
N. Gangat, N. Szuber, Tabinda Jawaid, C. Hanson, A. Pardanani, A. Tefferi   +5 more
semanticscholar   +1 more source

Essential thrombocythemia

Orphanet Journal of Rare Diseases, 2007
Essential thrombocythemia (ET) is an acquired myeloproliferative disorder (MPD) characterized by a sustained elevation of platelet number with a tendency for thrombosis and hemorrhage. The prevalence in the general population is approximately 30/100,000.
Brière Jean B
doaj   +1 more source